Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection
about
Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic CriteriaNeuroimaging biomarkers of neurodegenerative diseases and dementiaApplication of fused lasso logistic regression to the study of corpus callosum thickness in early Alzheimer's diseaseWhite matter tract integrity metrics reflect the vulnerability of late-myelinating tracts in Alzheimer's disease.Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.After disappointments, Alzheimer's researchers seek out new paths: biomarkers and combination therapies may lead to disease-modifying treatments, experts say.Lower Activation in Frontal Cortex and Posterior Cingulate Cortex Observed during Sex Determination Test in Early-Stage Dementia of the Alzheimer Type.Changes of EEG Spectra and Functional Connectivity during an Object-Location Memory Task in Alzheimer's Disease.Differential prefrontal and subcortical circuitry engagement during encoding of semantically related words in patients with late-life depression.Imaging biomarkers associated with cognitive decline: a review.Diffusion tensor imaging reveals visual pathway damage in patients with mild cognitive impairment and Alzheimer's disease.Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.The Structural and Functional Connectome and Prediction of Risk for Cognitive Impairment in Older AdultsDiagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.Bridging Integrator 1 (BIN1) Genotype Effects on Working Memory, Hippocampal Volume, and Functional Connectivity in Young Healthy Individuals.Identification of promethazine as an amyloid-binding molecule using a fluorescence high-throughput assay and MALDI imaging mass spectrometry.Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?Comparisons of neurodegeneration over time between healthy ageing and Alzheimer's disease cohorts via Bayesian inference.Vincamine Alleviates Amyloid-β 25-35 Peptides-induced Cytotoxicity in PC12 CellsCognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis.White Matter Deterioration May Foreshadow Impairment of Emotional Valence Determination in Early-Stage Dementia of the Alzheimer Type.Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease.Neural correlates of cognitive intervention in persons at risk of developing Alzheimer's disease.Neuroimaging Feature Terminology: A Controlled Terminology for the Annotation of Brain Imaging Features.Benefits and risks of add-on therapies for Alzheimer's disease.Neuronal Pentraxin 2 predicts medial temporal atrophy and memory decline across the Alzheimer's disease spectrum.Gender-Specific Degeneration of Dementia-Related Subcortical Structures Throughout the Lifespan.Multidimensional encoding of brain connectomes.Confidentiality in preclinical Alzheimer disease studies: when research and medical records meet.The prevalence and biomarkers' characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database.Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.Characterizing biomarker features of cognitively normal individuals with ventriculomegaly.Probability of Alzheimer's disease in breast cancer survivors based on gray-matter structural network efficiency.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.A 3-Month Aerobic Training Program Improves Brain Energy Metabolism in Mild Alzheimer's Disease: Preliminary Results from a Neuroimaging Study.APOE ε4 associated with preserved executive function performance and maintenance of temporal and cingulate brain volumes in younger adults.Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings.Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's diseaseCerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease
P2860
Q26864063-1FB517FE-56F9-44C9-B3E2-3C3A3D139226Q27691820-3E0DC504-C4F5-47D4-9BDA-E21C6208AE42Q30486417-F2C8598C-974A-4559-A527-441E3C9E0D66Q30711356-9AAF63B7-1AF4-4708-85CD-65A902D29AECQ30871982-34B1A8E9-B55C-4FC6-AAFF-7BE40EADA4F1Q33642389-2AC7188C-30D5-400D-A00E-5DDC50CC2D81Q33710738-E92BEC05-7AAA-40FC-9268-012AE282331AQ33741463-294464D7-B229-4FAC-ADFE-36E785A7F54CQ35111767-AC10C378-0424-4A44-905C-5AD27F8AB294Q35185786-2FFFCBFD-CCCC-4C8A-9166-C3C89FDD2E0CQ35845253-B46A263F-8221-4B9F-8319-6646BF6B44C8Q36001286-CF1FC3DE-8306-406B-A398-4D9B28E55441Q36733387-3118A9F6-4DFD-419A-827F-FEB6911451B7Q36885492-D0141A66-0570-449C-8610-182AE00EA90CQ37024864-4478DD29-C7D5-4E0C-86EA-326DD92F0E59Q37185672-AE68E0E0-8F04-4FD3-BAD7-779672C9E0C2Q37431101-6646EFCB-398E-4529-BDAA-F1F64192646EQ37639968-AA59E500-C88B-46AC-9362-5ED47B801065Q37640781-A75D401D-19A0-4332-A2B5-1C616D5C5756Q37650253-26B95F43-ABA4-45D4-9A6C-F72F861F4DE3Q37672378-F97E4068-2265-476C-A547-F128A8BF288BQ38210117-F322CE53-7F93-4261-9218-6FAA77953A2CQ38222874-CB224D67-511E-47F7-AB16-0E23D7A07AD3Q38247987-011116BB-1D3C-484E-AB56-A198EC1D9886Q38430889-586884F0-D573-424B-8264-2E61EF769FB1Q38620338-8F86656A-E32C-4CD7-BE93-B5DD6E1CE2D2Q38839061-68B33582-4E0F-4B79-89F7-F37DFA71FF68Q38993591-C7165110-80B0-46D4-A58E-5C4907045715Q41125217-8FE8BE54-DC21-42C4-98CB-B561445A5154Q42006679-3004B6FF-077F-4E29-A95D-21863CD0BD42Q42656101-CD4B52DD-ECC7-425C-BE7A-081DCC081BC6Q46082316-5F9A12C5-6E0E-4E88-B6F7-884AC7002F84Q47152383-EEAB8DB5-D5E4-4E13-BD8E-D1437AE86184Q47162779-DAEC7709-5260-4B51-869C-13418E7D893CQ47587631-751BA252-6321-457D-B117-9DA9C96ABFA5Q48001267-CCC9CE44-8FB8-4536-876A-2DD0C1C36F63Q48064744-2C921813-03CE-486C-B616-7F57EFA2F564Q53172274-CE22239F-C63C-49B8-9F9A-2183C429AC33Q57493750-585DC11D-2F62-486D-9CB0-BE63F6A11350Q58773968-C1B3AD60-BBD3-407A-972A-EC79CD9E7204
P2860
Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neuroimaging and other biomark ...... g landscape of early detection
@en
Neuroimaging and other biomark ...... landscape of early detection.
@nl
type
label
Neuroimaging and other biomark ...... g landscape of early detection
@en
Neuroimaging and other biomark ...... landscape of early detection.
@nl
prefLabel
Neuroimaging and other biomark ...... g landscape of early detection
@en
Neuroimaging and other biomark ...... landscape of early detection.
@nl
P2860
P921
P1476
Neuroimaging and other biomark ...... g landscape of early detection
@en
P2860
P304
P356
10.1146/ANNUREV-CLINPSY-050212-185535
P577
2013-01-07T00:00:00Z